Early Effects of Parathyroid Hormone (PTH) on the Proximal Femur

• Status: Completed
• Trial end date: 2015-08-01
• Target enrollment: 0
• Participant gender: All

Summary

Teriparatide is a potent osteoporosis medication that helps prevent fractures, however, the investigators know little about its effect on the hip. The investigators will evaluate hip bone samples from patients treated with teriparatide before undergoing hip replacement. The information will help us understand how teriparatide might help reduce hip fracture risk.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Health Research, Inc.
• Collaborators: Hospital for Special Surgery, New York; National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
• Treatments: Teriparatide

Criteria

Inclusion Criteria:

• Age 50-90 years old.

• Male or postmenopausal (women who have had no menses for one year)

• Degenerative joint disease of the hip (osteoarthritis) requiring total hip arthroplasty, based on radiologic and clinical impression.

Exclusion Criteria:

• Any contraindications to use of TPTD.

• Age younger than 50, greater than 90 years old.

• Metabolic bone disease other than osteoporosis.

• History of hyperparathyroidism without surgical correction.

• Unexplained hypercalcemia.

• Paget's disease (or unexplained elevated bone alkaline phosphatase level).

• History of any metastatic cancer or osteosarcoma.

• Prior radiation treatment.

• Secondary hyperparathyroidism due to vitamin D deficiency or renal disease. Active hyperthyroidism or excessive thyroid hormone replacement (with TSH below normal range).